newsfilter
← Latest News
Business Wire·

ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2025

Achieves $5.3 Million First Quarter Revenue, Reaches Milestone Developing Antibodies End-to-End Using LENSai IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ:IPA), an artificial intelligence-driven